Common JFDA Application Deficiencies for Chinese Manufacturers in Jordan

1. Key takeaways

GRZAN groups the frequent reasons for rejected applications by Chinese manufacturers in Jordan into six categories: insufficient remaining validity of certificates, incomplete consular legalisation, missing or non-compliant Arabic labelling, AR commercial registration scope mismatches, reference-country evidence in the wrong form, and technical documentation not organised according to JFDA reading habits. Of these, the first three are problems that can be fully avoided through process management, which is why they deserve to be treated as scheduling failures rather than regulatory mysteries.

The second takeaway: rejections mostly occur at the formal review stage, not the technical assessment stage. This means the main loss is time (resetting queues and appointments), not technical capability — the product usually survives the review; the paperwork is what fails first.

The third takeaway: after Circular No. 54863/1/5 of October 9, 2025 took effect, the consequences of rejection for Class IIb products were amplified — without a registration certificate, importation is impossible, and a rejection converts directly into a supply interruption rather than merely a delayed launch.

2. Legal basis

Clause numbers are subject to the Arabic originals published in the Jordanian Official Gazette and by the JFDA; the deficiency list is a practical estimate compiled from field experience. The table shows where each failure point is anchored: import conditions, documentary form, the Class IIb import gate, and the quality system certificate requirement.

3. Expert insights

Insight one: insufficient certificate validity is the most preventable rejection reason. GRZAN recommends ensuring that the ISO 13485 or country-of-origin GMP certificate has at least 6 months of remaining validity on the submission date (practical estimate). This item can be avoided entirely through registry management and scheduling, since certificate expiry dates are known years in advance.

Insight two: consular legalisation is the step most often underestimated in time. Notarisation and consular legalisation of the FSC and the letter of authorisation usually takes 4 to 6 weeks (practical estimate), with the embassy stage the least controllable part. Companies often run it in parallel with document preparation, and then the appointment arrives before the originals do, which defeats the whole schedule.

Insight three: Arabic label defects concentrate on prominence and three mandatory items. The font size, colour contrast and layout prominence of Arabic characters must not be inferior to the English; the product name, the local agent’s name and the JFDA registration number must all be stated in Arabic (practical estimate). Most label rejections trace back to one of these specific points rather than to the translation quality itself.

Insight four: AR commercial registration scope mismatch is the leading problem on the entity qualification line. The commercial registration certificate is issued by the Ministry of Industry, Trade and Supply, and its registered scope must cover the import of medical devices or medical consumables. Before selecting an AR, companies should request and verify the original, because the scope printed on that document decides whether the AR can lawfully clear the goods at all.

Insight five: the form requirements for reference-country evidence are frequently overlooked. The import directives require the original or a recently certified true copy. Colour scans and uncertified photocopies do not satisfy the requirement, however faithful the scan may be.

Insight six: how the technical file is organised affects assessment efficiency. JFDA technical assessment carries pharmaceutical review DNA, and acceptance is high for finished product specifications, analytical methods, certificates of analysis and stability data. Organising material along these preferences reduces deficiency queries (practical estimate), which shortens the review cycle without changing the substance of the file.

4. Practical recommendations

First, establish six gate checks before submission. Certificate validity, legalisation status, Arabic labelling, AR registration scope, reference-country evidence form and technical file organisation must all be ticked before filing, so that no application leaves the building with a known defect.

Second, schedule consular legalisation at the very front of the project. Start issuing and legalising the FSC and the letter of authorisation during AR selection, in parallel, so the longest and least controllable step runs while nothing else is blocked.

Third, set a higher quality gate for Class IIb products. After the 2025 circular took effect, the consequence of rejection escalated from delayed market entry to interrupted importation, which changes the cost of every shortcut.

Fourth, build a deficiency knowledge base. Every set of JFDA deficiency comments should be archived and fed back into later applications, so the same problems do not recur across products or across years.

5. Verification checklist

• □ The ISO 13485 or country-of-origin GMP certificate has at least 6 months of remaining validity (practical estimate)
• □ Notarisation and consular legalisation of the FSC and letter of authorisation are complete (allow 4–6 weeks, practical estimate)
• □ Arabic label prominence and the three mandatory items comply with the rules
• □ The AR commercial registration certificate covers device or consumable importation
• □ Reference-country evidence is the original or a certified true copy
• □ The technical file is organised to JFDA reading habits (including finished product specifications, analytical methods and similar)
• □ A higher quality gate is set for Class IIb products (Circular No. 54863/1/5, 2025-10-09)
• □ A mechanism exists for archiving and reusing JFDA deficiency comments
• □ Cited clause numbers are verified against the Arabic originals of the Official Gazette

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages adverse event reporting and recall coordination with the JFDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com